The company
Aurinia Pharmaceuticals Inc - Common Shares
AUPH · Nasdaq
AUPH stood above a rising 150-day average in 47 of the last 52 weekly readings, including each of the last 8 weeks. It is 4.1% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Just started moving
- Weeks in an uptrend
- 8 in a row
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $50.3M
- Insider sales, 12 months
- $1.1M
- Officials’ trades on record
- 0
- Institutions holding
- 268 (+24)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 47 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Stephen P. RobertsonChief Legal Officer | sold | 11,939at $15.95 | 10 Sep 2026filed 11 Sep 2026 |
| Stephen P. RobertsonChief Legal Officer | sold | 20,975at $16.97 | 21 Aug 2026filed 25 Aug 2026 |
| Kevin TangChief Executive Officer | bought | 206,005at $15.28 | 2 Jun 2026filed 2 Jun 2026 |
| Kevin TangChief Executive Officer | bought | 343,521at $15.28 | 1 Jun 2026filed 2 Jun 2026 |
| Kevin TangChief Executive Officer | bought | 99at $15.34 | 1 Jun 2026filed 2 Jun 2026 |
| Kevin TangChief Executive Officer | bought | 2,299at $15.35 | 29 May 2026filed 2 Jun 2026 |
| Kevin TangChief Executive Officer | bought | 262,682at $15.31 | 29 May 2026filed 2 Jun 2026 |
| Kevin TangDirector | bought | 184,208at $14.22 | 3 Mar 2026filed 3 Mar 2026 |
| Kevin TangDirector | bought | 83,561at $14.33 | 2 Mar 2026filed 3 Mar 2026 |
| Kevin TangDirector | bought | 115,792at $14.21 | 2 Mar 2026filed 3 Mar 2026 |
| Kevin TangDirector | bought | 300,000at $13.90 | 27 Feb 2026filed 3 Mar 2026 |
| Kevin TangDirector | bought | 214,839at $14.12 | 27 Feb 2026filed 3 Mar 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| TANG CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026 | 13,044,106$221.4M | +814,606+6.7% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 8,193,085$139.0M | +347,564+4.4% |
| GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026 | 5,619,401$95.4M | +4,185,893+292.0% |
| NEA Management Company, LLCunchanged · filed 14 Aug 2026 | 3,969,834$67.4M | 00.0% |
| TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026 | 3,467,514$58.8M | +38,809+1.1% |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIPreduced · filed 13 Aug 2026 | 3,264,062$55.4M | -20,306−0.6% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 2,589,615$43.9M | +62,516+2.5% |
| MORGAN STANLEYadded · filed 13 Aug 2026 | 2,308,244$39.2M | +75,696+3.4% |
| MARSHALL WACE, LLPadded · filed 13 Aug 2026 | 2,044,007$34.7M | +169,410+9.0% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 1,701,152$28.9M | +165,143+10.8% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.